에 대한 최신 뉴스 AquaBounty Techs (NASDAQ:AQB) 주식

AquaBounty Techs

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Technologies Inc

AUSTRALIAN UNITED INVST by AUSTRALIAN UNITED INVESTMENT CO LTD.

Aab National Co

On May 11, 2025, Incyte Corporation (the "Company") and Novartis Pharma AG ("Novartis") entered into a settlement agreement (the "Settlement Agreement") with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalties relating to the dispute with Novartis included in accrued and other current liabilities on the Company's condensed consolidated balance sheet. Under the Settlement Agreement, the Company has agreed to pay to Novartis $280.0 million as the settlement of disputed royalties on net sales of JAKAFI in the United States through December 31, 2024, and the parties agreed to reduce by 50% the royalty rate payable by the Company on future net sales of JAKAFI in the United States beginning January 1, 2025 for a period defined in the Settlement Agreement. The reduced royalty payable for the quarter ended March 31, 2025, is approximately $14.9 million. The difference of $242.2 million between the total accrued royalties and the total amount to be paid by the Company to Novartis as disclosed above will be recorded in the Company's condensed consolidated statement of operations for the quarter ending June 30, 2025.

News

Contracts

Legal

INCY

Incyte And Novartis Settle Royalty Dispute With $280M Payment And 50% Reduction In Future JAKAFI U.S. Royalties, Resolving Litigation Over 2009 Collaboration Agreement And Releasing $242.2M In Accrued Liabilities

Leerink Partners analyst Daina Graybosch downgrades ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) from Outperform to Market Perform and lowers the price target from $47 to $9.

Downgrades

Price Target

Analyst Ratings

ITOS

Leerink Partners Downgrades ITeos Therapeutics to Market Perform, Lowers Price Target to $9

Channel Therapeutics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NYSE">CHRO</a>) announced on Wednesday that it has achieved its predefined endpoints in two preclinical animal models for eye drop formulations (CT2000) for acute ocular and chronic ocular surface pain commonly associated <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">with dry eye disease</a>.&nbsp;
"We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42552299/channel-therapeutics-announces-positive-efficacy-data-for-a-depot-formulation-of-a-nav1-7-inhibito" rel="noreferrer noopener">announced in December 2024</a>, demonstrating a viable path forward in treating both post-surgical pain and chronic eye pain," stated Dr. Eric Lang, Chief Medical Officer of Channel.
"Additionally, these results support our belief that the inhibition of NaV1.7 has broad applications in treating different pain indications and further supports the genetic validation that NaV1.7 is a potent target for pain," concluded Dr. Lang.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44858815/exclusive-ligand-subsidiary-pelthos-therapeutics-to-combine-with-channel-therapeutics-creating-pain-medicines-focused-entity" rel="noreferrer noopener">EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity</a>
In the first trial, rabbits were treated with capsaicin (i.e., Pepper spray) to mimic an acute ocular insult.
<ul class="wp-block-list">
<li>Following the capsaicin treatment, the rabbits were treated with CT2000, which was dosed four times over 24 hours.</li>
<li>Pain was measured by the number of paw wipes over 60 seconds (paw wipes are a recognized surrogate of eye pain in animal models).</li>
<li>The results showed that CT2000 significantly reduced the number of paw wipes within 15 minutes of administering capsaicin and continued to show efficacy over 60 minutes following administration. </li>
</ul>
In the second trial, benzalkonium chloride (BAC) was instilled in the eyes of mice over a multiday period to create a model of dry eye disease (the study was repeated twice).
<ul class="wp-block-list">
<li>BAC is a detergent that irritates the eyes and simulates dry eye disease.</li>
<li>Following the induction of dry eye using BAC, the mice were dosed with CT2000 four times daily for seven days.</li>
<li>CT2000 reduced the frequency of paw wipes within a single day of administration and showed cumulative efficacy over time (the analgesic effect appeared to improve when dosed over several days). </li>
</ul>
"We are very encouraged with these results, and the opportunity to target a large market that currently does not have many therapeutic options could provide Channel with considerable market opportunities," stated Frank Knuettel II, CEO of Channel. "Moreover, these results pave the way for Channel to launch Phase 1/2 human proof of concept trials," Mr. Knuettel concluded.
According to Astute Analytica, the global annual chronic eye pain market was valued at $7.2 billion in 2023 and is projected to reach $12.4 billion by 2032, at a compound annual growth rate of 6.6% from 2024 to 2032.
According to Marketresearch.biz, the global annual acute eye pain market was valued at $404 million. The company intends to target this existing market with CT2000 and the postoperative pain market.
Price Action: CHRO stock closed at $1.07 on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45394076/cpi-undershoots-but-core-inflation-stays-stubborn-jp-morgan" target="_blank" rel="noreferrer noopener">CPI Undershoots But Core Inflation Stays Stubborn: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

CHRO

EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models

WIIM

QNRX

Quoin Pharmaceuticals shares are trading higher after the company announced initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study.

Earnings

Earnings Misses

ALCO

UPDATE: Alico Q2 Adj. EPS $(10.98), Sales $17.98M Miss $22.20M Estimate

Back in 1995, Bill Gates appeared on The Late Show with David Letterman, where he tried to explain what the internet was to the host, and seemingly predicted the emergence of AI.
What Happened: During their <a href="https://www.youtube.com/watch?v=fs-YpQj88ew">conversation</a>, Letterman asked Gates about the value of the then-new internet. Gates described it as a space "where people are publishing information," noting, "everybody can have their own homepage… it&#8217;s wild what&#8217;s going on."
When Letterman pushed him to share what he thought the future of the computer might be, Gates said: "Eventually we may figure out how to make the computer think… that turns out to be a very tough problem… nobody knows when that&#8217;ll happen. Some people think it&#8217;ll never happen." When Letterman quipped, "We don&#8217;t want them to think, do we?" Gates responded, "Not really… it&#8217;s a scary thought."
See Also: <a href="https://www.benzinga.com/25/05/45379222/former-google-ceo-eric-schmidt-in-2016-outlined-a-playbook-predicting-chatgpts-rise-and-a-new-age-of-100-billion-ai-giants">Former Google CEO Eric Schmidt In 2016 Outlined A Playbook Predicting ChatGPT&#8217;s Rise — And A New Age Of $100 Billion AI Giants</a>
Why It Matters: Although this conversation took place in 1995, before AI as we know it was developed, Gates' skepticism has persisted. Earlier this year, he listed <a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues">improper development of AI</a> as one of the critical challenges future generations will face, alongside nuclear war, bioterrorism and climate change.  
Last year, he highlighted a paradox at the heart of AI's unprecedented rise: while it promises to reduce the need for human effort and increase leisure time, it also raises questions about <a href="https://www.benzinga.com/news/24/12/42438799/bill-gates-predicts-ai-in-the-workforce-will-lead-to-so-much-leisure-time-but-itll-create-a-what-do-we-do-with-all-that-time-problem">how humans use that time</a>. He also emphasized the importance of regulatory oversight to prevent harm, such as biased results or dangerous misinformation.
In a recent television appearance, Gates pointed out that <a href="https://www.benzinga.com/news/25/05/45342962/bill-gates-slams-trumps-tariffs-we-told-china-to-make-their-own-chips-and-theyre-making-great-progress-warns-its-a-bad-time-to-inte">U.S. tariffs and tech restrictions have accelerated China&#8217;s move towards self-reliance</a>, especially in chip development. He highlighted that with open-source tools accessible globally, no single country is likely to dominate AI.
Read Next: <a href="https://www.benzinga.com/25/05/45377433/bill-gates-announces-plan-to-close-the-gates-foundation-says-hell-give-away-virtually-all-of-his-wealth-over-the-next-20-years">Bill Gates Announces Plan To Close The Gates Foundation, Says He&#8217;ll Give Away &#8216;Virtually All&#8217; Of His Wealth Over The Next 20 Years</a>
Image via Shutterstock

Entertainment

Markets

Tech

Bill Gates Once Warned That Computers Might Eventually Think On Their Own—But Admitted It Was A 'Scary Thought' That 'No One Knows When That Will Happen'

LUCY

Innovative Eyewear shares are trading higher after the company reported better-than-expected Q1 sales results.

ZVRA

Zevra Therapeutics shares are trading higher after the comapny reported better-than-expected Q1 financial results.

JP Morgan analyst Michael Cho assumes Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) with a Neutral rating and announces Price Target of $18.

Initiation

FRGE

JP Morgan Assumes Forge Global Holdings at Neutral, Announces Price Target of $18

Avis Budget Announced That Its Wholly-owned Subsidiaries Intend, Subject To Market And Other Customary Conditions, To Offer $500M Aggregate Principal Amount Of Senior Notes Due 2032 In A Private Offering

OpenAI chief Sam Altman describes Airbnb CEO Brian Chesky as someone who loves to express his individuality and influence through his work as a founder, a quality he thinks comes through during Airbnb&#8217;s launches.
What Happened: Altman lit up X after Chesky posted a teaser for Airbnb's sweeping overhaul, writing, "Brian is the most auteur founder of this generation, and it really shines through in how he does launches!" and later adding, "the new app design is so great."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">brian is the most auteur founder of this generation, and it really shines through in how he does launches! <a href="https://t.co/BSgjUsCMzq">https://t.co/BSgjUsCMzq</a>
&mdash; Sam Altman (@sama) <a href="https://twitter.com/sama/status/1922372362420256960?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Altman's praise landed hours after Chesky unveiled Airbnb's radical shift in the direction of being an &#8220;everything app.&#8221; "Now, you can Airbnb more than an Airbnb," Chesky told a Tuesday crowd, promising to turn every trip or hometown weekend into a curated itinerary.
Chesky introduced the three pillars for the platform: Airbnb Services, a re-engineered Airbnb Experiences, and an all-new app tying them together. The headline addition, Airbnb Services, lets users in 260 cities book in-home chefs, massages, personal trainers and even makeup artists, matching perks long monopolized by hotels.
See also: <a href="https://www.benzinga.com/markets/equities/25/05/45402695/teslas-robotaxi-plans-under-federal-scrutiny-ahead-ff-austin-launch-as-elon-musk-vows-nationwide-rollout-by-year-end">Tesla&#8217;s Robotaxi Plans Under Federal Scrutiny Ahead Ff Austin Launch As Elon Musk Vows Nationwide Rollout By Year-End</a>
The rebooted Experiences hub ditches bus-tour clichés for five lanes—history &amp; culture, food &amp; drink, nature &amp; outdoors, art &amp; design, and fitness &amp; wellness — ranging from restoring Notre Dame with its architects to ramen lessons from Michelin-star chefs.
Airbnb is also rolling out Originals, limited-slot events hosted by names like Megan Thee Stallion and NFL MVP Patrick Mahomes.
A ground-up app redesign was also launched at the event, which features countdown widgets, interactive icons and AI-driven suggestions into a single itinerary view that mashes lodging, services and experiences.
Why It Matters: Wall Street analysts <a href="https://www.benzinga.com/25/05/45175845/wall-street-reacts-as-airbnb-eyes-growth-amid-us-slowdown-details">told Benzinga</a> the summer release is meant to open new revenue lanes as Airbnb's core bookings mature, even as regulatory and hotel competition pressures persist.
Altman, in a blog post earlier this year, publicly stated that Chesky and SV Angel founder Ron Conway did "incredible and gigantic amounts of work" helping him during his <a href="https://www.benzinga.com/news/23/12/36171063/what-really-happened-with-sam-altman-getting-fired-as-openai-ceo-new-details-emerge">brief ouster from OpenAI</a> in November 2023. Altman added that the pair "stopped me from making several mistakes," and suggested OpenAI might not still be standing without their support.
Photo by Boumen Japet via Shutterstock
Read next: <a href="https://www.benzinga.com/news/25/05/45403040/jeff-bezos-became-a-billionaire-after-taking-this-leap-of-faith-would-you-have-the-stomach-for-his-regret-minimization-strategy">Jeff Bezos Became A Billionaire After Taking This Leap Of Faith: Would You Have The Stomach For His &#8216;Regret-Minimization&#8217; Strategy?</a>

Brian Chesky Shares Promo For Airbnb's Biggest Change In Decades, Sam Altman Calls Him 'The Most Auteur Founder Of This Generation'

MediPharm Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MEDIF#OTC">MEDIF</a>) reported quarterly sales of $7.53 million which missed the analyst consensus estimate of $10.54 million by 28.59 percent. This is a 3.85 percent increase over sales of $7.25 million the same period last year.

MEDIF

MediPharm Labs Q1 Sales $7.53M Miss $10.54M Estimate

<ul class="wp-block-list">
<li>Walgreens has plans to expand its use of robot-powered micro-fulfillment centers</li>
<li>The centers currently serve 4,800 stores, and fill more than 16 million prescriptions each month</li>
<li>The push for automation comes as Walgreens prepares to go private in a deal with Sycamore Partners</li>
</ul>
Walgreens will be expanding its use of prescription-filling robots, <a href="https://www.cnbc.com/2025/05/11/walgreens-doubles-down-on-robots-to-fill-prescriptions-amid-turnaround.html">CNBC</a> reports.
The pharmacy chain began using micro-fulfillment centers in 2021 before pausing the program in 2023 to focus on feedback and improvement. Now, it&#8217;s working to add more in order to free up time for pharmacy staff, reduce time spent on routine tasks, and eliminate inventory waste.
The robot-powered centers fill thousands of prescriptions for patients who use medication to manage conditions like diabetes and high blood pressure. With those tasks automated, Walgreens told CNBC its pharmacy staff will have more time to interact directly with patients and perform clinical services like vaccinations and testing.
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
The company told CNBC it hopes to have 11 micro-fulfillment centers serving 5,000 locations by the end of the year. In February, there were 4,800 stores that utilized the micro-fulfillment centers. On average, these centers handled 40% of the prescription volume at the individual locations, Walgreens says, which translates to about 16 million prescriptions filled each month across all serviced stores.
Kayla Heffington, Walgreens' pharmacy operating model vice president, told CNBC that the company's investment in automation is already paying off. The micro-fulfillment centers have generated $500 million in savings through their increased efficiency and reduction of excess inventory. Stores that use the centers are also administering 40% more vaccines than those that aren't, increasing profits.
"Right now, [the micro-fulfillment centers] are the backbone to really help us offset some of the workload in our stores, to obviously allow more time for our pharmacists and technicians to spend time with patients," Rick Gates, Walgreens' chief pharmacy officer, told CNBC. "It gives us a lot more flexibility to bring down costs, to increase the care and increase speed to therapy – all those things."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Gates added that he sees the micro-fulfillment centers as a competitive advantage for Walgreens, because many independent pharmacies and larger rivals don't have the centralized support. However, many of Walgreens' major competitors, like Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), and Albertsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), already have, or are testing, their own versions of the micro-fulfilment facilities.&nbsp;
There are, of course, risks that come with using these micro-fulfillment centers, like a reliance on sophisticated robotics that can cause major disruptions if errors occur. But for Walgreens, the rewards heavily outweigh the risks.
Heffington told CNBC that the automated locations have helped reduce prescription fulfillment costs by nearly 13% year over year, and have increased prescription volume by 126%. The centers also allow the company to have real-time data on all prescription fulfillments, enabling its employees to provide better customer service.&nbsp;
The renewed push for automation comes as Walgreens prepares to go private in a <a href="https://investor.walgreensbootsalliance.com/news-releases/news-release-details/walgreens-boots-alliance-enters-definitive-agreement-be-acquired">$10 billion deal with Sycamore Partners</a>. The buyout is expected to be complete by the end of the year.&nbsp;
Read Next:
<ul class="wp-block-list">
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
</ul>
Image: Shutterstock

Personal Finance

Walgreens To Expand Use Of Prescription-Filling Robots, Cites $500 Million In Savings As Motive

EXCLUSIVE: Channel Therapeutics Tells Benzinga Co. Announces Results For The Treatment Of Eye Pain Using NaV1.7 Inhibitor In Multiple Preclinical In Vivo Models

RCAT

Red Cat Holdings shares are trading higher after the company announced the expansion of its multi-domain Family of Systems with a new line of Unmanned Surface Vessels.

VERV

Verve Therapeutics shares are trading higher after the company reported a year-over-year increase for Q1 EPS results.

ARCO

Arcos Dorados Holdings shares are trading lower after the company reported mixed Q1 financial results.

GRAL

GRAIL shares are trading lower after the company reported mixed Q1 financial results.

ZYNLONTA&#xAE;&nbsp;plus glofitamab (COLUMVI&#xAE;) demonstrated&nbsp;ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refractory DLBCL
Safety and tolerability data were consistent with the known profiles of each agent
Updated data to be shared during poster presentation at EHA2025 on Saturday, June 14 at 12:30 p.m. ET and oral presentation at ICML on Friday, June 20 at 9:00 a.m. ET
LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ --&nbsp;ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with glofitamab in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Updated results will be shared at the European Hematology Association 2025 Congress (EHA2025) taking place in Milan, Italy with an oral encore presentation at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. Updated LOTIS-5 safety run-in data evaluating the combination of ZYNLONTA plus rituximab (Lonca-R) will also be featured at EHA2025.

ADCT

ADC Therapeutics Presents Data From LOTIS-7 Phase 1B Clinical Trial Evaluating ZYNLONTA In Combination With Glofitamab In Patients With r/r DLBCL

Jefferies analyst Philippe Houchois downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Buy to Hold and maintains the price target from $16 to $16.

RIVN

Jefferies Downgrades Rivian Automotive to Hold, Maintains Price Target to $16

Press Releases

David F. Melbourne Jr. Promoted to Chief Executive Officer of AquaBounty; Sylvia Wulf to Continue as Non-Executive Board Chair

Comments

AquaBounty Techs

뉴스

에 대한 최신 뉴스 AquaBounty Techs (NASDAQ:AQB) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌